Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial

Documents similaires

• Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma
  par: Takahiro Kinami, et autres
  Publié: (2024)
• Feasibility of atezolizumab and bevacizumab combination regimens in patients with hepatocellular carcinoma and lung cancer taking direct oral anticoagulants
  par: Tasuku Nakabori, et autres
  Publié: (2024)
• A case of biopsy‐proven acute interstitial nephritis following atezolizumab‐bevacizumab treatment of advanced unresectable hepatocellular carcinoma
  par: Reema Patel, et autres
  Publié: (2024)
• Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial
  par: Toshifumi Tada, et autres
  Publié: (2024)
• Patient‐reported outcome thresholds and their associations with survival, adverse events, and quality of life in a pooled analysis of breast cancer trials
  par: Bradley D. Menz, et autres
  Publié: (2025)